NCI-H508 In Vitro Comparative Genomic Hybridization (CGH) Assay
CAT#: ITS-1122-YF607
Target Cell Organism: Human
Target Cell Alternative Name: H508
Target Cell Name: NCI-H508
Assay Type: Genome Alteration Assays
Assay Overview
This assay is to provide NCI-H508-based In Vitro Comparative Genomic Hybridization (CGH) Assay to accelerate our client's oncology projects. The assay will be customized according to the specific requirements. Please contact our scientists to discuss more details.
Target Cell Name
NCI-H508
Target Cell Organism
Human
Target Cell Background
NCI-H508 [H508] is a cell line derived from metastasis to the abdominal wall obtained from a patient after treatment with 5-fluorouracil. NCI-H508 [H508] is from the cecum of a White, 55-year-old, male patient with colorectal adenocarcinoma. This cell line was deposited by AF Gazdar.
Target Cell Alternative Name
H508
Related Diseases
Colorectal Adenocarcinoma; Colon Cancer
Research Area
Oncology
Assay Name
In Vitro Comparative Genomic Hybridization (CGH) Assay
Short Description
NCI-H508-cell based In Vitro Comparative Genomic Hybridization (CGH) Assay
Assay Description
CGH is another popular cytogenetic technique, which is used to analyze copy number variations in genomes. In this technique, DNA in the reference sample (tumors) is first labeled with fluorochromes and allowed to hybridize with normal DNA. Human Cot-1 DNA is used to inhibit non-specific hybridization in this technique. Analyzing the ratio between fluorescence signal intensities of labeled DNA in samples and references can be plotted for each chromosome, permitting identification of possible copy number changes. CGH does not give much information about gene dosages and it is reported to be insensitive to structural abnormalities where copy number is not altered.
Assay Type
Genome Alteration Assays
Assay Type Details
Aberrant or somatic mutations are more commonly found in the DNA of cancer cells compared to normal cells. There is an equilibrium that exists between DNA damage and repair in normal cells. However, in cancer cells these events are disturbed, resulting in mutations and genomic instability. Genomic instability in cancer cells causes chromosomal aberrations, microsatellite instability, aneuploidy and uncontrolled gene amplifications and genetic instability in cancer cells are mainly due to point mutations or chromosomal aberrations such as insertions, deletions and translocation, resulting in mutated proteins.